![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Spark Therapeutics Proposes Value-Based Reimbursement, Installment Plans for Luxturna
Spark Therapeutics Proposes Value-Based Reimbursement, Installment Plans for Luxturna
January 8, 2018
Amid controversy over the high cost of its newly approved gene therapy Luxturna — $850,000 before discounts — Spark Therapeutics announced a series of initiatives to improve patient access to the drug, including outcomes-based arrangements with Harvard Pilgrim and Express Scripts.
The drug is a gene therapy for treatment of pediatric patients with biallelic RPE65 mutation-associated retinal dystrophy.
The arrangements will link payments to efficacy, with the amount the company collects hinging on the drug’s efficacy over both a 30-90-day period and a longer 30-month stretch, using light-sensitivity tests as an endpoint. The company is in talks with other commercial insurers for similar arrangements.
Upcoming Events
-
21Oct